These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35220251)

  • 1. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
    Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K
    Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
    Emancipator K; Huang L; Aurora-Garg D; Bal T; Cohen EEW; Harrington K; Soulières D; Le Tourneau C; Licitra L; Burtness B; Swaby R
    Mod Pathol; 2021 Mar; 34(3):532-541. PubMed ID: 33239737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2.
    Sato R; Komatsuda H; Inoue T; Wakisaka R; Kono M; Yamaki H; Ohara K; Kumai T; Kishibe K; Hayashi T; Takahara M
    Head Neck; 2024 Sep; 46(9):2233-2243. PubMed ID: 38665131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
    Okada T; Fushimi C; Matsuki T; Okamoto I; Sato H; Kondo T; Tokashiki K; Kishida T; Ito T; Yamashita G; Aihara Y; Hanyu K; Kushihashi Y; Masubuchi T; Tada Y; Miura K; Harada Y; Momiyama K; Yamashita T; Omura GO; Takahashi H; Oridate N; Tsukahara K
    Anticancer Res; 2022 Mar; 42(3):1607-1613. PubMed ID: 35220258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
    Tsujikawa T; Ohno K; Morita KI; Saburi S; Mitsuda J; Yoshimura K; Kimura A; Morimoto H; Ogi H; Shibata S; Akashi T; Kurata M; Imoto I; Shimizu Y; Kano S; Watanabe A; Yamazaki T; Asada Y; Hayashi R; Saito Y; Ozawa H; Tsukahara K; Oridate N; Sano D; Horii A; Ueki Y; Maruo T; Mukoyama N; Hanai N; Fukusumi T; Iwai H; Fujisawa T; Fujii T; Nibu KI; Iwae S; Ueda T; Chikuie N; Yasumatsu R; Matsuo M; Umeno H; Ono T; Masuda M; Toh S; Itoh K; Hirano S; Asakage T
    Front Immunol; 2024; 15():1390873. PubMed ID: 39136017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
    Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Chiu TJ; Huang TL; Chien CY; Huang WT; Li SH
    World J Surg Oncol; 2024 Sep; 22(1):242. PubMed ID: 39256833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
    Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
    Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
    Matsubara Y; Toriyama K; Kadowaki S; Ogata T; Nakazawa T; Kato K; Nozawa K; Narita Y; Honda K; Masuishi T; Bando H; Ando M; Tajika M; Oze I; Hosoda W; Muro K
    Esophagus; 2023 Jul; 20(3):524-532. PubMed ID: 36595124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
    Okamoto I; Tsukahara K; Sato H
    Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
    Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Yamashita G; Okamoto I; Ito T; Tokashiki K; Okada T; Tsukahara K
    Anticancer Res; 2023 Aug; 43(8):3679-3683. PubMed ID: 37500154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
    Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.